Supervisor Database Search
Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.
The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year. You can read the ICAT supervisor policy here.
Full NameDr Steven Gray
Clinical Medicine
Trinity College Dublin
Webpage:www.tcd.ie
Email Address:Email hidden; Javascript is required.
- genetics, genomics and molecular biology
- cell and developmental biology/regenerative medicine
- cancer/oncology
- clinical trials
- Other
Epigenetics
- Medicine
- Pathology
- Endocrinology
- Oncology
- Respiratory Medicine
Research in my lab includes:
1. Epigenetic mechanisms underpinning drug resistance in cancer.
2. Targeting Epigenetic Readers, Writers and Erasers in cancer
3. Circulating Tumour Cells in cancer
4. non-coding RNA repertoires in Prostate Cancer, Mesothelioma and Thoracic malignancy.
5. nanoparticles
6. Cancer Stem Cells
7. Utilizing epigenetic targeting agents to enhance onco-immunology
Recent Publications
1. MacDonagh L, Gray SG, et al. (2018). “Reversing cisplatin resistance in non‐small cell lung cancer using BBI608, a cancer stemness inhibitor”. Cancer Lett. 2018 Apr 10. pii: S0304-3835(18)30269-6. doi: 10.1016/j.canlet.2018.04.008.
2. Mohamed BM, Boyle NT, Schinwald A, Murer B, Ward R, Mahfoud OK, Rakovich T, Crosbie-Staunton K, Gray SGet al. (2018). “Induction of protein citrullination and auto-antibodies production in mice exposed to nickel nanomaterials”. Scientific Reports;8(1):679.
3. MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, et al. (2017). “Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC.” Oncotarget. 8(42):72544-72563.
4. Dockry É, O’Leary S, Gleeson LE, Lyons J, Keane J, Gray SG*, Doherty DG* “Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells” OncoImmunology In Press (* contributed equally to the direction of this study)